Sign In
Buy ADIL
$2.71
+0.110 (+4.23%)
At Close: Jun 22, 2026
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
08:00am, Tuesday, 16'th Jun 2026
GLEN ALLEN, Va., June 16, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company's Compensation Committee and Board of
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
11:43am, Thursday, 11'th Jun 2026
- Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mi
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
08:30am, Monday, 11'th May 2026
GLEN ALLEN, Va., May 11, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial's precision-medicine approach New U.S. utility
GLEN ALLEN, Va. , April 27, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies f
Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04's role in providing a treatment option for patients where existing treatme
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 49.4% in April
03:13am, Sunday, 26'th Apr 2026
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totaling 49,013 s
Demonstration batch production achieves all prespecified test specifications for dissolution, content uniformity, blend uniformity meeting regulatory requirements to start clinical drug product produc
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 21.7% in March
01:36am, Friday, 17'th Apr 2026
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) saw a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 96,887 shares, a growth
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Drop in Short Interest
02:28am, Tuesday, 17'th Mar 2026
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
09:00am, Tuesday, 24'th Feb 2026
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3 Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
08:30am, Monday, 23'rd Feb 2026
Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Submission for AD04 Regulatory Shift Could Significantly Lower Phase 3 Costs and Accelerate Path Toward NDA Subm
Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL)
02:08am, Wednesday, 18'th Feb 2026
Adial Pharmaceuticals (NASDAQ: ADIL - Get Free Report) and Kaleido Biosciences (NASDAQ: KLDO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compar
GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing thera
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
04:05pm, Tuesday, 03'rd Feb 2026
Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026 Common Stock Will Begin Trading on Split-Adjusted Basis on February 6, 2026
